InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug ...

Singlera Genomics, a company focused on the application of novel DNA methylation technologies to genetic diagnosis, with their partner Breakthrough Genomics, a leader in the clinical analysis of ...

Sapu BioScience has been developing TGFB2-targeted antisense therapeutics, establishing one of the deepest proprietary knowledge bases around this pathway in oncology. That work has generated a broad ...

Three of the biotech industry’s trusted advisory firms: KreaMedica, Venture Valuation, and Lacerta Bio, today announced the release of The First-Time Biotech CEO Playbook, a practical guide designed ...

Inventiva est une société cotée sur le compartiment B du marché réglementé d'Euronext Paris (symbole : IVA, ISIN : FR0013233012) et sur le Nasdaq Global Market aux États-Unis (symbole : IVA).

License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applications ...

Notably, the company completed its End-of-Phase 2 (EOP2) interactions with the U.S. Food and Drug Administration (FDA) and received scientific advice from the European Medicines Agency (EMA).

“The results of this first-in-child trial show some encouraging signals of activity in a highly aggressive chemotherapy resistant brain cancer, such as partial tumor response in a diffuse intrinsic ...

Lifeward selected Verita as its partner in these targeted regions to integrate ReWalk into their multi-modal treatment methodologies for people living with neurological and spinal cord injuries. Today ...

The recommendation to add COPIKTRA ( duvelisib) to the NCCN Guidelines is based on the broad body of evidence and uniform consensus ( > 85% support of the NCCN Panel) that intervention is appropriate.

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it has ...

Based on these data, SAB BIO has advanced SAB-142 into a registrational Phase 2b trial SAFEGUARD to evaluate SAB-142 in adult and pediatric patients with new-onset, stage 3 T1D. The SAFEGUARD trial is ...